MediciNova vs 60 Degrees Pharmaceuticals
MNOV and SXTP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MNOV and SXTP compare
MediciNova is the larger company, worth 38 times as much as 60 Degrees Pharmaceuticals ($68.7M against $1.8M).
60 Degrees Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −730% compared with −1127% at MediciNova.
60 Degrees Pharmaceuticals scores higher on the StockData Score (8 against 7 for MediciNova), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MNOV | SXTP |
|---|---|---|
| Size and price | ||
| Market cap | $68.7M | $1.8M |
| Share price | $1.40 | $0.518 |
| Change, 1 year | −11.1% | −89.5% |
| Change, 5 years | −56.5% | – |
| Beta (5Y) | 0.39 | 2.09 |
| Employees | 6 | 3 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 73.4× | 1.6× (better) |
| P/B | 1.7× | 0.7× (better) |
| FCF yield | −14.3% (better) | −488% |
| Fair value | – | $1.29 |
| Margin of safety | – | 59.7% |
| Growth | ||
| Revenue growth (TTM) | – | 73.2% |
| Profitability | ||
| Gross margin | – | 19.4% |
| Operating margin | −1232% | −775% (better) |
| Net margin | −1127% | −730% (better) |
| FCF margin | −1048% | −801% (better) |
| Return on equity | −24.8% (better) | −322% |
| Return on invested capital | −78.4% (better) | −659% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 (better) |
| Interest coverage | – | −1134.8× |
| Current ratio | 8.75 (better) | 2.32 |
| Altman Z-score | −3.99 (better) | −22.23 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 10.5% | 21.5% |
| Held by insiders | 12.8% | 21.0% |
| Insider net buying, 12 months | −$1.7M | $30.1K (better) |
| Short interest, % of float | 0.66% | – |
Go deeper
- MNOV stock overview
- MNOV income statement
- MNOV valuation and score
- SXTP stock overview
- SXTP income statement
- SXTP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.